cytarabine has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Chen, P; Hou, D; Huang, H; Li, D; Lin, X; Wang, B; Wang, X; You, R; Zhang, B; Zheng, X | 1 |
| Simmons, D; Yu, D; Zhao, Z | 1 |
2 other study(ies) available for cytarabine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells.
Topics: Animals; Cytarabine; Diabetes Mellitus, Type 2; Humans; Leukemia, Myeloid, Acute; Metformin; Mice; Mice, Nude; Mice, SCID; Mitochondria; Stromal Cells; Tumor Microenvironment | 2022 |
Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Comorbidity; Cytarabine; Diabetes Mellitus, Type 2; England; Female; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |